589 RESULTS
Sort By:
Humans who live longer display the same biomarkers found in laboratory animals who have restricted caloric intake. However, because these human subjects weren't actively restricting their caloric intake, there may be other ways to increase life span in humans...
Soon after the World Health Organization bestowed its approval on the protein 14-3-3 as an important diagnostic marker for sporadic Creutzfeldt-Jakob disease (sCJD), reports began to come in that its sensitivity and specificity might not be all that was advertised...
As the pipeline fills with potential therapies for Alzheimer (AD) and other neurodegenerative diseases, the research community is paying increased attention to...
People affected by early-onset familial forms (eFAD) often wonder how discoveries apply to them...
Calculating the risk of impending AD based on levels of CSF Aβ42 has been tricky because the peptide forms insoluble aggregates that muddle estimates of its production rate in the CNS...
People who complain of troubling memory lapses but show no impairment in standard memory tests may take some solace from a recent European study...
Though ApoE4 genotype has for years topped the list of genetic risk factors for AD, scientists grapple with how this allele makes people more prone to AD...
The Alzforum brings you a journalistic summary by reporter Pat McCaffrey enhanced by slide decks from the majority of presentations...
The last decade has seen study after study confirm that falling amyloid-β (Aβ) in the cerebrospinal fluid (CSF) is an indicator of incipient AD...
In the biomarker field, potential new indicators of disease risk and prognosis leap onto the scene, yet vanishingly few finish the journey to routine clinical use...
Having established the first 42 amino acids in Aβ as a valid biomarker for AD, researchers are now turning their attention to all the other fragments of APP in the CSF...
ALS has joined the growing list of neurodegenerative diseases characterized by fluctuations in the amino acid N-acetylaspartate (NAA)—but with a twist...
Continued setbacks in Alzheimer’s disease clinical trials have fueled a sense that candidate drugs have been tested in patients whose disease has already progressed too far...
Researchers have been measuring Aβ for decades, trying to nail down its behavior in Alzheimer's patients or those nearing the disease...
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
